Arsenic Trioxide vs Nivolumab

## Arsenic Trioxide vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Arsenic Trioxide** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Arsenic Trioxide — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Arsenic Trioxide — Small molecule; Nivolumab — Antibody.